|
Real-time Estimate
Cboe BZX
11:43:25 2026-10-26 EDT
|
5-day change | 1st Jan Change | ||
| 6.935 USD | +0.07% |
|
-40.12% | -61.78% |
| 10-23 | Avalo Therapeutics Shares Fall After HC Wainwright Downgrade | MT |
| 10-23 | Guggenheim Downgrades Avalo Therapeutics to Neutral From Buy | MT |
Company Valuation: Avalo Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 190.9 | 47.45 | 7.295 | 77.74 | 329.3 | 371.7 | - | - |
| Change | - | -75.15% | -84.63% | 965.79% | 323.58% | 12.86% | - | - |
| Enterprise Value (EV) 1 | 190.9 | 47.45 | 7.295 | 77.74 | 231 | -52.34 | 66.11 | -55.14 |
| Change | - | -75.15% | -84.63% | 965.79% | 197.1% | -122.66% | 226.29% | -183.42% |
| P/E | -2.05x | -1.14x | -0.08x | -0.94x | -3.11x | -2.44x | -2.52x | -2.63x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0x | 0x | 0x | 0.1x | 0x | 0.81x | 0.62x |
| Capitalization / Revenue | 35.4x | 2.63x | 3.79x | 176x | 5,582x | - | - | - |
| EV / Revenue | 35.4x | 2.63x | 3.79x | 176x | 3,915x | - | - | - |
| EV / EBITDA | - | - | - | - | - | 0.54x | -0.5x | - |
| EV / EBIT | -2.32x | -1.27x | -0.27x | -1.13x | -3.17x | 0.53x | -0.5x | 0.39x |
| EV / FCF | -2.69x | -1.77x | - | -1.58x | -4.49x | 0.64x | -0.59x | 0.4x |
| FCF Yield | -37.2% | -56.6% | - | -63.1% | -22.3% | 157% | -171% | 250% |
| Dividend per Share 2 | - | - | - | - | - | 0.0114 | 0.00075 | - |
| Rate of return | - | - | - | - | - | 0.16% | 0.01% | - |
| EPS 2 | -2,390 | -1,063 | -114 | -7.94 | -5.84 | -2.835 | -2.748 | -2.632 |
| Distribution rate | - | - | - | - | - | -0.4% | -0.03% | - |
| Net sales 1 | 5.398 | 18.05 | 1.924 | 0.441 | 0.059 | - | - | - |
| EBITDA 1 | - | - | - | - | - | -96.92 | -132.7 | - |
| EBIT 1 | -82.13 | -37.44 | -27.35 | -68.51 | -72.92 | -98.82 | -133.3 | -141.9 |
| Net income 1 | -84.38 | -41.66 | -31.54 | -35.13 | -78.26 | -100 | -132.5 | -155.9 |
| Net Debt 1 | - | - | - | - | -98.34 | -424 | -305.6 | -426.8 |
| Reference price 2 | 4,895.962 | 1,209.614 | 9.100 | 7.430 | 18.160 | 6.930 | 6.930 | 6.930 |
| Nbr of stocks (in thousands) | 39 | 39.2 | 802 | 10,464 | 18,134 | 53,630 | - | - |
| Announcement Date | 3/2/22 | 3/29/23 | 3/29/24 | 3/20/25 | 3/23/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.44x | - | 0.54x | - | 372M | |
| 18.83x | 6.63x | 13.18x | 1.58% | 64.69B | |
| 30.16x | 8x | 26.2x | 0.05% | 54.78B | |
| 36.79x | 6.53x | 19.51x | 0.88% | 53.49B | |
| 35.59x | 3.45x | 14.87x | -.--% | 45.98B | |
| 49.71x | 5.74x | 31.52x | -.--% | 42.94B | |
| -19.41x | 187.75x | -20.66x | -.--% | 40.08B | |
| 28.93x | 8.21x | 21.27x | 0.37% | 33.52B | |
| 27.67x | 5.83x | 15.12x | -.--% | 23.97B | |
| 32.59x | 5.97x | 20.28x | -.--% | 23.67B | |
| Average | 23.84x | 26.46x | 14.18x | 0.32% | 38.35B | |
| Weighted average by Cap. | 26.69x | 25.33x | 15.90x | 0.43% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AVTX Stock
- Valuation Avalo Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
